초록 ▼

The invention relates to a method for the solvent-free preparation of a homogenizate, especially for implants or microparticles, wherein one or more polymers andone or more active constituents, as raw materials, are homogenized together below the glass transition temperature of the polymer(s) and,

The invention relates to a method for the solvent-free preparation of a homogenizate, especially for implants or microparticles, wherein one or more polymers andone or more active constituents, as raw materials, are homogenized together below the glass transition temperature of the polymer(s) and, when homogenization is complete, brought to room temperature.

대표청구항 ▼

1. Solvent-free method of producing implants, comprising the steps of: (a) cooling together raw materials comprising at least one pharmaceutically active constituent and at least one polymer compatible therewith, said materials in the form of powders or granules, in a cryogenic mill to a temperature

1. Solvent-free method of producing implants, comprising the steps of: (a) cooling together raw materials comprising at least one pharmaceutically active constituent and at least one polymer compatible therewith, said materials in the form of powders or granules, in a cryogenic mill to a temperature applied in cryogenic technology;(b) completely homogenizing the raw materials together in said mill at a temperature below the glass transition temperature of the at least one polymer; and(c) thereafter bringing the homogenized raw materials to room temperature and obtaining the resulting homogenizatewherein said steps (a) to (c) are carried out in the absence of solvent; and(d) further processing the homogenizate obtained to form an implant;wherein the polymer is selected from one or more in the group consisting of poly(L-lactides), poly(D,L-lactides), poly(D,L-lactides-co-glycolides), and poly(L-lactides-co-D,L-lactides. 2. Method according to claim 1, comprising carrying out said cooling step to the temperature of dry ice or of a liquid gas. 3. Method according to claim 1, comprising carrying out said cooling step to the operating temperature of a cryogenic mill. 4. Method according to claim 1, comprising carrying out the process steps of cooling and homogenizing repeatedly in succession. 5. Method according to claim 1, comprising carrying out said homogenizing step mechanically. 6. Method according to claim 5, comprising carrying out said homogenizing step by grinding. 7. Method according to claim 1, comprising extruding and dividing the homogenizate into portions to form implant(s). 8. Method according to claim 2, comprising carrying out said cooling step to the temperature of liquid nitrogen. 9. Method according to claim 6, comprising carrying out grinding with the aid of a cryogenic mill. 10. An implant comprising the homogenizate of claim 1. 11. Method according to claim 1, wherein the at least one polymer compatible with the at least one pharmaceutically active constituent has a weight average molecular weight in a range of 5,000 to 80,000 Dalton. 12. Method according to claim 11, wherein the at least one pharmaceutically active constituent is selected from the group consisting of hypothalamus hormones and synthetic analogues thereof. 13. Method according to claim 11, wherein the at least one pharmaceutically active constituent is selected from the group consisting of cetrorelix, corticorelin, triptorelin, leuprorelin, gonadorelin, ganirelix, buserelin, nafarelin, goserelin and/or derivatives thereof and/or pharmaceutically acceptable salts thereof. 14. Method according to claim 1, wherein the at least one pharmaceutically active constituent is selected from the group consisting of hypothalamus hormones and synthetic analogues thereof. 15. Method according to claim 1, wherein the at least one pharmaceutically active constituent is selected from the group consisting of cetrorelix, corticorelin, triptorelin, leuprorelin, gonadorelin, ganirelix, buserelin, nafarelin, goserelin and/or derivatives thereof and/or pharmaceutically acceptable salts thereof. 16. Method according to claim 1, wherein the at least one pharmaceutically active constituent is selected from the group consisting of LH-releasing hormone and synthetic analogues thereof. 17. Solvent-free method of producing implants, comprising the steps of: (a) feeding raw materials comprising at least one pharmaceutically active constituent and at least one polymer compatible therewith, said materials in the form of powders or granules, into a cryogenic mill;(b) cooling the combination of raw materials in the cryogenic mill to a temperature applied in cryogenic technology;(c) completely homogenizing the raw materials together in said mill at a temperature below the glass transition temperature of the at least one polymer; and(d) thereafter bringing the homogenized raw materials to room temperature and obtaining the resulting homogenizatewherein said steps (a) to (d) are carried out in the absence of solvent; and(e) further processing the homogenizate obtained to form an implant;wherein the at least one polymer compatible with the at least one pharmaceutically active constituent is selected from the group consisting of poly(L-lactides), poly(D,Llactides), poly(D,L-lactides-co-glycolides), poly(L-lactides-co-D,L-lactides), and combinations thereof. 18. Method according to claim 11, wherein the at least one pharmaceutically active constituent is selected from the group consisting of LH-releasing hormone and synthetic analogues thereof. 19. Solvent-free method of producing implants, comprising the steps of: (a) feeding raw materials comprising at least one pharmaceutically active constituent and at least one polymer compatible therewith, said materials in the form of powders or granules, into a cryogenic mill;(b) cooling the combination of raw materials in the cryogenic mill to a temperature applied in cryogenic technology;(c) completely homogenizing the raw materials together by grinding in said mill at a temperature below the glass transition temperature of the at least one polymer; and(d) thereafter bringing the homogenized raw materials to room temperature and obtaining the resulting homogenizatewherein said steps (a) to (d) are carried out in the absence of solvent; and(e) further processing the homogenizate obtained to form an implant;wherein the at least one polymer compatible with the at least one pharmaceutically active constituent is selected from the group consisting of poly(L-lactides), poly(D,Llactides), poly(D,L-lactides-co-glycolides), poly(L-lactides-co-D,L-lactides), and combinations thereof. 20. Method according to claim 16, wherein the ratio of the polymer(s) to active constituent(s) is selected such that the content of the pharmaceutically active constituent(s) is from 5% to 50% by weight, based on the weight of the homogenisate. 21. Method according to claim 19, wherein the raw materials are cooled together and subsequently homogenized.